co occurrence of aortic dissection and polycystic kidney disease a case report

Original title: “Co-occurrence of aortic dissection and polycystic kidney disease: a case report.”

A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.

Original title: “Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod”

While Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a different kidney disease.

Original title: “Vertex opens up larger kidney disease opportunity with mid-stage readout”

rare pkhd1 frameshift variant identified in a prenatally diagnosed arpkd case from a consanguineous jordanian family

Original title: “A Rare PKHD1 Frameshift Variant Identified in a Prenatally Diagnosed ARPKD Case From a Consanguineous Jordanian Family.”

fibrocystin c terminal domain inhibits src stat3 signal induced cystogenesis of kidney epithelial cells

Original title: “The fibrocystin C-terminal domain inhibits Src/STAT3 signal induced cystogenesis of kidney epithelial cells.”

mislabeling no more what kidney biopsies reveal in diabetes

Original title: “Mislabeling No More: What Kidney Biopsies Reveal in Diabetes.”

cell type specific damage scores reveal kidney and liver disease trajectories in single cell and spatial transcriptomics

Original title: “Cell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomics.”

Boulevard Bio launches with $65M from Deerfield to advance multi-specific antibody programs for autoimmune diseases The LSX USA Congress gathers leaders from the US biotech, medtech, and healthtech sectors to network, showcase innovations, and explore partnership opportunities. The New York-based biotech debuts with quarterly-dosing antibody for kidney disease and precision immunology platform backed entirely by Deerfield Management. She studied English Literature at university and started her journalism career as a reporter and then editor of BioProcess Insider. Millie is especially interested in deals and dealmakers across the life sciences space and loves to write about the ins and outs of partnerships and investments. The clinical-stage company, backed entirely by Deerfield Management and its affiliates, is advancing three multi-specific antibody programs that aim to deliver more durable disease control with significantly less burdensome treatment schedules for patients managing chronic autoimmune conditions.

Original title: “Boulevard Bio exits stealth with $65m funding”

advanced mri methods for children and young adults with autosomal recessive polycystic kidney disease arpkd to support future multi center clinical trials

Original title: “Advanced MRI methods for children and young adults with autosomal recessive polycystic kidney disease (ARPKD) to support future multi-center clinical trials.”

impact of african enriched gatm regulatory variants on creatinine derived estimated glomerular filtration rate

Original title: “Impact of African-enriched GATM regulatory variants on creatinine-derived estimated glomerular filtration rate.”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 9891: To direct the Secretary of Health and Human Services to conduct a demonstration program to share savings with plans that invest in preventing the progression of kidney disease to end-stage renal disease.”

comparison of preemptive living donor kidney transplantation with incident hemodialysis in japan a region specific analysis from a setting with limited deceased donor kidney transplantation

Original title: “Comparison of preemptive living-donor kidney transplantation with incident hemodialysis in Japan: a region-specific analysis from a setting with limited deceased-donor kidney transplantation.”

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Original title: “Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker”

oral microbiota mediates the association of healthy dietary patterns with lower risk of advanced cardiovascular kidney metabolic syndrome

Original title: “Oral microbiota mediates the association of healthy dietary patterns with lower risk of advanced cardiovascular-kidney-metabolic syndrome.”

renin cells orchestrate a neuro endocrine microenvironment of the kidney arterial tree in health and disease

Original title: “Renin cells orchestrate a neuro-endocrine microenvironment of the kidney arterial tree in health and disease.”

evaluation of the association between age sex and d amino acid based estimation of glomerular filtration rate

Original title: “Evaluation of the Association between Age, Sex and d-Amino Acid-Based Estimation of Glomerular Filtration Rate.”